XOMA Royalty Corp

XOMA Royalty Corporation is a biotech royalty aggregator that acquires and manages economic rights to milestone payments and royalties from therapeutic drug development programs. The company holds a diversified portfolio of rights tied to both commercial and pre-commercial candidates across various therapeutic areas, generating revenue through these downstream payment streams rather than through direct drug development or commercialization.

The company's portfolio comprises two primary asset categories. The first consists of early to mid-stage clinical assets in Phase 1 and 2 development that are licensed to partners, with the company retaining economic rights to future milestones and royalties. The second includes late-stage clinical or commercial assets where the company has acquired established milestone and royalty revenue streams. This portfolio-based approach allows the company to generate recurring revenue from multiple programs at varying stages of development and commercialization.

XOMA Royalty operates with a lean organizational structure of 13 full-time employees and is headquartered in Emeryville, California. The company maintains a geographic focus on the United States and Asia Pacific regions. XOMA Royalty was formerly known as XOMA Corporation and underwent a corporate restructuring with its name change in July 2024, reflecting its transformation into a royalty-focused business model.